Stay updated on Olaparib in Metastatic Prostate Cancer (PROfound Study) Clinical Trial

Sign up to get notified when there's something new on the Olaparib in Metastatic Prostate Cancer (PROfound Study) Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Olaparib in Metastatic Prostate Cancer (PROfound Study) Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-05-22T07:45:51.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    16 days ago
    Change Detected
    Summary
    The recent change on the webpage indicates a disclaimer stating that the U.S. government does not review or approve the safety and science of all studies listed on the website. This disclaimer was added to the information about the completed study of Olaparib (Lynparza™) versus Enzalutamide or Abiraterone Acetate in men with metastatic castration-resistant prostate cancer (PROfound Study).
    Difference
    26%
    Check dated 2024-05-08T22:18:29.000Z thumbnail image
  7. Check
    17 days ago
    Change Detected
    Summary
    The value of the variable 'R' on the webpage has recently changed.
    Difference
    20%
    Check dated 2024-05-07T12:37:05.000Z thumbnail image
  8. Check
    24 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T21:54:36.000Z thumbnail image

Stay in the know with updates to Olaparib in Metastatic Prostate Cancer (PROfound Study) Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Olaparib in Metastatic Prostate Cancer (PROfound Study) Clinical Trial page.